Theinfluenzavaccinefieldhasbeenconstantlyevolvingtoimprovethespeed,scalability,andflexibilityofmanufacturing,andto
improvethebreadthandlongevityoftheprotectiveimmuneresponseacrossagegroups,givingrisetoanarrayofnextgeneration
vaccinesindevelopment.Amongthese,therecombinantinfluenzavaccinetetravalent(RIV4),usingabaculovirusexpressionvector
systemtoexpressrecombinanthaemagglutinin(r HA)ininsectcells, istheonlyonetohavereachedthemarketandhasbeen
studiedextensively. Wedescribehowtheuniquestructuralfeaturesofr HAin RIV4improveprotectiveimmuneresponsescompared